In this study, TP-6076 was well tolerated and there were no serious or severe adverse events, or discontinuations due to an adverse event. There were no clinically significant safety findings in any laboratory assessments, vital signs, ECGs or physical examinations. The most frequently reported adverse events in the TP-6076 groups were gastrointestinal, which consisted primarily of nausea in the highest dose group, no vomiting was reported. Following single IV doses of TP-6076, exposure to TP-6076 increased in a slightly greater than dose proportional manner.TP-6076 is a novel, synthetic, fluorocycline antibiotic candidate being developed for the treatment of serious and life-threatening bacterial infections, including those caused by pathogens otherwise resistant to current treatment options. It has demonstrated potent in vitro activity against multidrug-resistant bacteria including carbapenem-resistant Enterobacteriaceae and carbapenem-resistant Acinetobacter baumannii. Safety, Tolerability and Pharmacokinetics of Single Intravenous Doses of TP-271, a Novel Fluorocycline Antibiotic This poster presentation described data from a phase 1 randomized, double-blind, placebo-controlled, single-ascending-dose, single-center study evaluating the safety, tolerability and pharmacokinetics of IV TP-271. The study was conducted at a single center in 56 healthy volunteers. Seven cohorts of 8 subjects each were randomized 6:2 to receive single doses ranging from 0.15 mg/kg up to 5 mg/kg, or placebo. TP-271 was well tolerated at single doses that resulted in high plasma exposures. There were no clinically significant changes in lab values, ECG parameters, or physical exam findings. There were no serious or severe adverse events, or discontinuations due to an adverse event during the study. The most frequently reported adverse events in the TP-271 groups were gastrointestinal, which consisted of nausea and vomiting occurring mostly in the highest dose group. Following single IV doses of TP-271, plasma exposures increased as dose increased in a greater than dose-proportional manner. TP-271 is a novel, broad-spectrum antibiotic candidate which is being developed to combat respiratory disease caused by bacterial biothreats and antibiotic-resistant public health pathogens, including Francisella tularensis, Yersinia pestis and Bacillus anthracis, as well as bacterial pathogens associated with community-acquired bacterial pneumonia. Tetraphase is developing TP-271 with funding from the National Institutes of Health's National Institute of Allergy and Infectious Diseases, which supports preclinical development, manufacturing and phase 1 clinical, safety and pharmacokinetic evaluation of TP-271. In preclinical studies, TP-271 has demonstrated potency against Gram-negative and Gram-positive pathogens associated with respiratory tract infections. ASM Microbe 2017 is the integration of two of the American Society of Microbiology's meetings: the General Meeting and ICAAC (Interscience Conference on Antimicrobial Agents and Chemotherapy). Requests for presentations can be sent to Medical Affairs through the Tetraphase website at https://www.tphase.com/our-science/clinical-programs/. About Tetraphase Pharmaceuticals, Inc.Tetraphase is a clinical-stage biopharmaceutical company using its proprietary chemistry technology to create novel antibiotics for serious and life-threatening bacterial infections, including those caused by many of the multidrug-resistant (MDR) bacteria highlighted as urgent public health threats by the CDC. Tetraphase has created more than 3,000 novel tetracycline analogs using its proprietary technology platform. Tetraphase's pipeline includes three antibiotic clinical candidates: eravacycline, which is in phase 3 clinical trials, and TP-271 and TP-6076, which are in phase 1 clinical trials. Please visit www.tphase.com for more company information.
Investor Contacts:Tetraphase PharmaceuticalsTeri Dahlman617firstname.lastname@example.orgArgot PartnersMaeve Conneighton206.email@example.comMedia Contact:Sam Brown Inc.Mike Beyer312-961-2502Mikebeyer@sambrown.com